Descripción de la empresa
Nuvation Bio Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of product candidates specifically designed for cancer treatment, with its primary focus centered on oncology therapeutics. The company functions within the Healthcare sector, specifically the Biotechnology industry, a classification that signifies its engagement in the high-risk, high-reward phase of bringing novel biological treatments from the laboratory to the clinic. Currently, the organization employs a workforce of 298 individuals and holds a market capitalization of $1.57 billion, generating total annual revenue of $62.90 million in the trailing twelve months. These financial figures indicate that Nuvation Bio occupies a mid-to-large capitalization position within the biotechnology landscape, possessing sufficient liquidity to fund its clinical development pipeline while maintaining a substantial operational footprint relative to many early-stage peers.
Salud financiera
In the trailing twelve months, the company reported a revenue of $62.90 million, a net income of $-204,627,008, and an EBITDA of $-211,324,992, revealing a significant gap where costs substantially exceed earnings before interest, taxes, and non-operating expenses. This substantial disparity between positive revenue and deep negative net income highlights an aggressive cost structure typical of clinical-stage companies, where research and development expenditures, regulatory costs, and operational overheads dominate the financial statement before any profit is realized. The free cash flow stands at $-115,776,248, which indicates that the company is currently consuming cash reserves to fund its operations and clinical trials rather than generating surplus cash for immediate distribution or aggressive balance sheet expansion. The gross margin is recorded at 85.2%, suggesting high pricing power or low direct manufacturing costs relative to sales, while the operating margin of -81.3% and profit margin of 0.0% reflect the heavy burden of general and administrative expenses, research costs, and the inherent lack of profitability in the current development stage. On the balance sheet, the company holds $529.21 million in cash against $66.94 million in debt, resulting in a debt-to-equity ratio of 21.90, which suggests a leveraged position where debt exists but is covered by significant cash holdings. The current ratio of 6.95 indicates a highly conservative stance regarding short-term liquidity, as the company possesses nearly seven times the current assets necessary to cover its current liabilities, providing a robust buffer against immediate financial obligations. Furthermore, the return on equity is -53.2% and the return on assets is -23.5%, metrics that reveal that management is currently generating negative returns on the capital deployed, a common characteristic for biotechnology firms reinvesting all earnings into product development rather than shareholder returns.
Evaluación de valoración
The trailing P/E ratio is listed as N/A due to the company's lack of earnings, while the forward P/E is -31.10, a metric that implies the market is pricing the stock based on future earnings expectations that are currently negative or undefined, rather than historical profitability. The price-to-book ratio stands at 5.11, indicating that the market values the company at more than five times its book value, which suggests a significant premium assigned to the company's intangible assets, such as its intellectual property portfolio and clinical data, rather than its tangible net assets. Alternative valuation metrics such as the price-to-sales ratio of 24.92 and the EV/EBITDA of -5.23 suggest that investors are valuing the company primarily on its revenue generation potential and pipeline value rather than current earnings power or cash flow generation. Regarding trading ranges, the 52-week high is $9.75 and the 52-week low is $1.57, meaning the stock is trading within a wide volatility band that reflects the speculative nature of clinical-stage biotechnology equities. The beta value of 1.61 indicates that the stock price is expected to be 61% more volatile than the broader market, suggesting that price movements will likely exceed those of the general equity market during periods of increased volatility.
Growth & Income
The company has demonstrated explosive revenue growth of 633.1% year-over-year, whereas earnings growth is listed as N/A, indicating that while sales are expanding rapidly, profitability has not yet been achieved to the extent required to calculate a traditional earnings growth rate. As a non-dividend payer, Nuvation Bio maintains a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company does not distribute cash to shareholders but instead retains all available capital to fuel its research and development activities. This reinvestment strategy is standard for clinical-stage biopharmaceutical firms, where the primary objective is to advance product candidates through clinical trials and secure regulatory approval rather than to generate immediate income for shareholders. Consequently, the overall growth and income profile is characterized by substantial revenue expansion driven by new sales or commercialization, coupled with a complete absence of dividend income, reflecting a capital allocation strategy focused entirely on long-term asset building and clinical progress.